A Phase 1 interventional study of HMPL-760 and Rabeprazole and HMPL-760 in Healthy Participants, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Hutchmed · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants. The study consists of a screening period, a dosing period (Cycles 1, 2, 3, and 4), and a follow-up period. Screening must occur within 14 days prior to the first dose of study drug. Enrolled participants will be randomly assigned to one of 6 dosing sequences in the ratio of 1:1:1:1:1:1 to complete Cycles 1-3 dosing to evaluate the effect of different types of food on the PK of HMPL-760, and then to receive rabeprazole and HMPL-760 in Cycle 4 to assess the effect of PPI on the PK of HMPL-760 (see dosing sequence table for details).
Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in treatment A will fast overnight for at least 10 hours prior to HMPL-760 dosing.
Drug: HMPL-760
All participants in treatment B will receive a standardized high-fat meal approximately 30 minutes before HMPL-760 administration
Drug: HMPL-760
All participants in treatment C will receive a standardized low-fat meal approximately 30 minutes before HMPL-760 administration
Drug: HMPL-760
All participants receive rabeprazole 20 mg orally QD(Quaque Die) 1 h before the breakfast on Day 15 and the morning of Day 16 to Day 20. Rabeprazole and HMPL-760 are orally administered concomitantly under fasted conditions on the morning of Day 21.
Drug: Rabeprazole and HMPL-760
300 mg HMPL-760 will be administered orally once daily on Day 1, Day 6 and Day 11.
Drug pages: Rabeprazole · BTK Inhibitor HMPL-760
20 mg of rabeprazole will be administered orally once daily in the morning from Day 15 to Day 21, and a 300 mg oral dose of HMPL-760 will be administered concomitantly with rabeprazole on Day21.
AUC 0-last
Area under the plasma concentration-time curve from time zero to the last time point t where the concentration could be accurately determined
Time frame: Day 1 to Day 25
AUC 0-inf
Area under the plasma concentration-time curve from time 0 to infinity
Time frame: Day 1 to Day 25
Cmax
Maximum plasma concentration
Time frame: Day 1 to Day 25
Tmax
Time to Cmax
Time frame: Day 1 to Day 25
tlag
Lag Time
Time frame: Day 1 to Day 25
t1/2
Terminal elimination half-life
Time frame: Day 1 to Day 25
Adverse events rate
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
Time frame: Day 1 to Day 32(±1 day)
Laboratory tests
Number of participants with abnormal laboratory tests results
Time frame: Day 1 to Day 32(±1 day)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2026 to primary completion in Jul 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BTK Inhibitor HMPL-760 · Rabeprazole